Beneath anxiety, people-pleasing, and burnout often lies a fragile self-relationship. Here’s how to start loving yourself in ...

The authors' prior article “Mastering Accounting Communication with Storytelling and Data Visualization” (May/June 2025) ...

Alkermes reports positive results from Vibrance-2 phase 2 study of once-daily alixorexton in patients with narcolepsy type 2: Dublin Friday, November 14, 2025, 18:00 Hrs [IST] Alk ...

For Medicaid care management, focusing on rising-risk patients is more effective than targeting high-cost claimants, whose spending tends to decrease over time due to regression to the mean.

Q3 2025 Earnings Call November 6, 2025 8:30 AM ESTCompany ParticipantsVipin Garg - President, CEO & DirectorLinda Richardson ...

Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate Efficacy in a Large Phase 2 Study in Patients With ...

As stablecoin market cap hits US$232bn, industry experts debate whether traditional banks should compete with or integrate ...

Q3 2025 Earnings Call November 5, 2025 11:00 AM ESTCompany ParticipantsJason Tremblay - Vice President of Enterprise Strategy ...

A presentation by scientists on a work group for the Centers for Disease Control and Prevention’s vaccine advisory panel ...

Chepkwony, I. and Keter, J. (2025) Impact of Library Resource Utilization on Secondary School Students’ Performance in Chemistry at Uasin Gishu County, Kenya. Open Journal of Social Sciences, 13, ...

AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...